To include your compound in the COVID-19 Resource Center, submit it here.

I-Mab looks to fill gap in NASDAQ listings by Chinese players

I-Mab Biopharma is hoping to become only the second innovative Chinese drug developer since Zai two years ago to go public on NASDAQ.

The Shanghai-based company has proposed to raise up to

Read the full 315 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers